Needham & Company LLC Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $22.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective lifted by Needham & Company LLC from $14.00 to $22.00 in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages also recently weighed in on STOK. HC Wainwright reaffirmed a buy rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. Canaccord Genuity Group upped their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a buy rating in a research report on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a neutral rating in a research note on Tuesday. Finally, TD Cowen raised shares of Stoke Therapeutics from a market perform rating to an outperform rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $19.63.

Stoke Therapeutics Stock Down 4.7 %

Shares of NASDAQ:STOK opened at $13.50 on Tuesday. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.40. The firm has a 50-day simple moving average of $6.07 and a 200 day simple moving average of $5.02. The company has a market cap of $625.05 million, a PE ratio of -5.70 and a beta of 0.68.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total value of $48,000.00. Following the transaction, the insider now owns 6,981 shares in the company, valued at approximately $33,508.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total value of $48,000.00. Following the transaction, the insider now owns 6,981 shares in the company, valued at approximately $33,508.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,615 shares of company stock worth $212,852. 12.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after purchasing an additional 837 shares during the period. American International Group Inc. increased its position in shares of Stoke Therapeutics by 10.9% during the 2nd quarter. American International Group Inc. now owns 10,506 shares of the company’s stock worth $139,000 after purchasing an additional 1,029 shares in the last quarter. Great West Life Assurance Co. Can increased its position in shares of Stoke Therapeutics by 46.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock worth $28,000 after purchasing an additional 1,078 shares in the last quarter. Ensign Peak Advisors Inc acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $25,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $27,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.